Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized PRRT in Neuroendocrine Tumors
NCT02754297Phase 2Active, not recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Apr 2016
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in neuroendocrine tumors (NETs), sponsored by CHU de Québec-Université Laval. Primary endpoint: Objective Response Rate at 3 months. Started Apr 2016; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02754297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754297.